Abstract：
Aim: To investigate associations of MEOX2 expression with clinicopathological features and survival of breast cancer patients. Materials & methods: We used a breast cancer tissue microarray for immunohistochemistry. Associations between MEOX2 expression and clinicopathological features were analyzed using the χ-square test. Survival analysis was determined using a Kaplan-Meier curve. Multivariate Cox regression was used to determine associations of MEOX2 expression with overall survival. Results: We found that 74.1% of patients (100/135) had expression of MEOX2 at varying levels. MEOX2 was associated with histological grade and negatively correlated with Ki67 expression. Lower MEOX2 expression was significantly associated with decreased overall survival (p = 0.0011). Conclusion: MEOX2 expression could be a novel diagnostic and prognostic biomarker of breast cancer.
In this study we found that lower expression of the protein MEOX2 was associated with poor overall survival in breast cancer. MEOX2 is an independent prognostic factor for breast cancer patients. It would be a new diagnostic and prognostic biomarker for breast cancer.
In this study we found that lower expression of the protein MEOX2 was associated with poor overall survival in breast cancer. MEOX2 is an independent prognostic factor for breast cancer patients. It would be a new diagnostic and prognostic biomarker for breast cancer.
摘要：
目的:探讨MEOX2表达与乳腺癌患者临床病理特征及生存的关系。材料和方法：我们使用乳腺癌组织微阵列进行免疫组织化学。使用χ平方检验分析MEOX2表达与临床病理特征之间的关联。使用Kaplan-Meier曲线测定生存分析。多变量Cox回归用于确定MEOX2表达与总生存期的相关性。结果：我们发现74.1%的患者（100/135）有不同水平的MEOX2表达。MEOX2与组织学分级相关，与Ki67表达呈负相关。较低的MEOX2表达与总生存率降低显著相关(p=0.0011)。结论：MEOX2的表达可能是乳腺癌诊断和预后的新生物标志物。
在这项研究中，我们发现MEOX2蛋白的低表达与乳腺癌患者的低总生存率相关。MEOX2是乳腺癌患者的独立预后因素。它将成为乳腺癌诊断和预后的新生物标志物。
在这项研究中，我们发现MEOX2蛋白的低表达与乳腺癌患者的低总生存率相关。MEOX2是乳腺癌患者的独立预后因素。它将成为乳腺癌诊断和预后的新生物标志物。
